Drug General Information
Drug ID
D0R7JT
Former ID
DAP001105
Drug Name
Fludrocortisone
Synonyms
Alflorone; Astonin; FCOL; Florinef; Fludrocortisona; Fludrocortisonum; Fludrocortone; Fludrone; Fludronef; Fluodrocortisone; Fluohydrisone; Fluohydrocortisone; Fluorocortisol; Fluorocortisone; Astonin H; Astonin Merck; Merck Brand of Fludrocortisone; StC 1400; U 5963; ZK5; Astonin-H; F-COL; F-Cortef;Florinef (TN); Fludrocortisona [INN-Spanish]; Fludrocortisone (INN); Fludrocortisone [INN:BAN]; Fludrocortisonum [INN-Latin]; Merck, Astonin; Astonin-H (TN); Hydrocortisone-9alpha-fluoro; Pregn-4-ene-3,20-dione, 9-fluoro-11beta,17,21-trihydroxy-(8CI); (11beta)-9-Fluoro-11,17,21-trihydroxypregn-4-ene-3,20-dione; (8S,9R,10S,11S,13S,14S,17R)-9-fluoro-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; 9 .alpha. FF; 9 Fluoro 17 Hydroxycortisone; 9 Fluorocortisol; 9 Fluorohydrocortisone; 9 alpha FF; 9 alpha Fludrohydrocortisone; 9 alpha Fluoro 17 Hydroxycorticosterone; 9 alpha Fluorohydrocortisone; 9 alpha-Fludrocortisone; 9 alpha-Fluoro-17-Hydroxycorticosterone; 9 alpha-Fluorocortisol; 9 alpha-Fluorohydrocortisone; 9-Fluoro-11-beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11.beta.,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-11beta,17,21-trihydroxypregn-4-ene-3,20-dione; 9-Fluoro-17-Hydroxycortisone; 9-Fluorocortisol; 9-Fluorohydrocortisone; 9-alpha-Fludrocortisone; 9-alpha-Fluoro-17-hydroxycorticosterone; 9-alpha-Fluorocortisol; 9-alpha-Fluorohydrocortisone; 9.alpha.-Fluoro-11.beta.,17.alpha.,21-trihydroxy-4-pregnene-3,20-dione; 9.alpha.-Fluoro-17-hydroxycorticosterone; 9.alpha.-Fluorocortisol; 9.alpha.-Fluorohydrocortisone; 9alpha-Fludrocortisone; 9alpha-Fluoro-11beta,17alpha,21-trihydroxy-4-pregnene-3,20-dione; 9alpha-Fluoro-17-hydroxycorticosterone; 9alpha-Fluoro-hydrocortisone; 9alpha-Fluorocortisol
Drug Type
Small molecular drug
Indication Cerebral salt-wasting syndrome [ICD10:E87.1] Approved [538426], [539899]
Therapeutic Class
Antiinflammatory Agents
Structure
Download
2D MOL

3D MOL

Formula
C21H29FO5
InChI
InChI=1S/C21H29FO5/c1-18-7-5-13(24)9-12(18)3-4-15-14-6-8-20(27,17(26)11-23)19(14,2)10-16(25)21(15,18)22/h9,14-16,23,25,27H,3-8,10-11H2,1-2H3/t14-,15-,16-,18-,19-,20-,21-/m0/s1
InChIKey
AAXVEMMRQDVLJB-BULBTXNYSA-N
CAS Number
CAS 127-31-1
PubChem Compound ID
PubChem Substance ID
ChEBI ID
ChEBI:50885
SuperDrug ATC ID
H02AA02
SuperDrug CAS ID
cas=000127311
Target and Pathway
Target(s) Mineralocorticoid receptor Target Info Agonist [535856], [537575]
KEGG Pathway Aldosterone-regulated sodium reabsorption
PathWhiz Pathway Kidney Function
WikiPathways ACE Inhibitor Pathway
References
Ref 538426FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (NDA) 010060.
Ref 539899(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2873).
Ref 535856Mineralocorticoid receptor-mediated inhibition of the hypothalamic-pituitary-adrenal axis in aged humans. J Gerontol A Biol Sci Med Sci. 2003 Oct;58(10):B900-5.
Ref 537575Addison's disease. BMJ. 2009 Jul 2;339:b2385. doi: 10.1136/bmj.b2385.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.